The COVID-19 pandemic is continuing to cause major global disruption to the activities of development stage and other life sciences companies due to, among other factors, limited or no access to clinical trial sites, reduced supply levels for active pharmaceutical ingredients or other key materials needed to make drug candidates or medical devices, and the inability of personnel to access laboratory and other specialized work spaces.
The post Collaboration, License and other Commercial Agreements: Key Considerations for Life Sciences Companies in the Age of COVID-19 appeared first on Life Sciences Perspectives.